Monday, February 16, 2026
28
C
Bengaluru
Hot topics
Eli Lilly’s Acquisition of Adverum Signals Focus on Gene Therapies to Redefine Eye Care
Eli Lilly’s planned acquisition of Adverum Biotechnologies is a...
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Is Your Field Force Optimised to Make the Most of Market Growth in Metros?
Summary of Performance of Top 30 Metros in IPM...
Creating A Winning Sales Organisation – Workshop Announcement
MedicinMan catches up with Deep Bhandari - Advisor at UCB where he...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Hot topics
ZS Bets Big on India as Pharma GCCs Rewrite the Global Life Sciences Playbook
With its latest expansion, ZS is placing a decisive...
Deep Bhandari: Human capital holds the highest value for organizations
DigiStorm 2018 was held on 11 September at the Lalit Ashok in Bangalore. The event was headlined by Prabir Jha – President & Global Chief People Officer, Cipla. Deep Bhandari – Editorial Board Member, MedicinMan, gives us the highlights of the post-lunch session.
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Newsletter
Get important news delivered directly to your inbox and stay connected!